FREMONT, Calif., Nov. 5 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genetic analysis systems, today announced that Christopher Sears, Ph.D. has joined the company's Scientific Advisory Board. His career has been focused on designing and commercializing novel molecular diagnostics for cancer detection and other applications, and on the development of computational biology systems for several biotechnology companies and academic institutions.
"We are very pleased to welcome Dr. Sears and I am confident that his previous successes developing diagnostic products coupled with his unique background designing critical software systems, will be highly valuable for WaferGen," said Alnoor Shivji, CEO, WaferGen. "Our flagship SmartChip Real Time PCR technology is becoming an important tool for academic researchers and pharmaceutical companies requiring improved approaches to gene expression profiling. Dr. Sears' experience in all phases of product development, from design through to commercialization will be a strong fit for WaferGen."
"I am looking forward to joining WaferGen's Scientific Advisory Board as I believe the SmartChip technology offers significant untapped potential for a host of applications requiring improved genetic analysis," said Christopher Sears, Ph.D. "My background lends itself to assisting WaferGen now as the company seeks to ramp up its collaborations and become the leading platform for gene expression work. I see multiple benefits offered by this technology and am pleased to be able to be a part of what I believe will be a true, next-generation advance in the medical field."
Dr. Christopher Sears is currently the Chief Scientific Officer at Ambergen, responsible for overseeing the development of molecular diagnostic platforms for cancer, HIV, autoimmune, and other diseases. Prior to this, Dr. Sears held joint academic appo
|SOURCE WaferGen Biosystems, Inc.|
Copyright©2009 PR Newswire.
All rights reserved